Therapy with anti–vascular endothelial growth factor (anti-VEGF) agents has dramatically improved visual outcomes for patients with various retinal vascular diseases, including retinal vascular occlusion, diabetic macular edema, and neovascular age-related macular degeneration. Landmark phase 3 randomized clinical trials comparing anti-VEGF alternatives have answered key questions regarding their comparative effectiveness in these diseases.1-3 However, a remaining issue that faces physicians is how to choose an anti-VEGF dosing regimen that optimizes visual outcomes while avoiding unnecessary procedures and patient visits.
Sun JK. The SCORE2 Comparison of Treat-and-Extend vs Monthly Anti–Vascular Endothelial Growth Factor Dosing: Short-term Similarities and Longer-term Questions. JAMA Ophthalmol. 2018;136(4):346–347. doi:10.1001/jamaophthalmol.2017.6855
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: